Despite that doxorubicin alone or in combination with TAT significantly inhibited tumor growth compared to the negative control (PBS) (Figure 4F–H), the tumors in the group treated with doxorubicin plus TAT‐PEP were smallest among all groups (Figure 4F–H), indicating that blocking ATAD3A phosphorylation with TAT‐PEP enhanced tumor sensitivity to doxorubicin. The gene discussed is ATAD3A; the disease is neoplasm.